| Dr Brenton Haskell, MD | |
|
10095 Investment Way, Florence, KY 41042 | |
| (859) 301-9050 | |
| Not Available |
| Full Name | Dr Brenton Haskell |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Occupational Medicine |
| Location | 10095 Investment Way, Florence, Kentucky |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1225191398 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083X0100X | Preventive Medicine - Occupational Medicine | 39060 (Kentucky) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brenton Haskell, MD 164 Clubhouse Dr, Georgetown, KY 40324-9070 Ph: () - | Dr Brenton Haskell, MD 10095 Investment Way, Florence, KY 41042 Ph: (859) 301-9050 |
News Archive
Antigenics Inc. (NASDAQ:AGEN) today announced that the Brain Tumor Research Center at the University of California, San Francisco, has begun enrolling patients into a Phase 2 clinical trial of Oncophage (vitespen) in combination with the standard of care - radiation therapy plus Temodar (temozolomide) - for newly diagnosed glioma patients.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that it has amended and expanded the scope of the protocol PV-10-LC-01, "A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma not Amenable to Resection or Transplant."
Researchers from the University of Pittsburgh's Swanson School of Engineering and McGowan Institute for Regenerative Medicine (MIRM) are proposing that if 3-D printers, or additive manufacturing, can produce custom replacement parts for machines, why couldn't the same process create biodegradable tissue repair structures for the human body?
Blood transfusions can save the lives of patients who have suffered major blood loss, but hospitals don't always have enough or the right type on hand. In search of a solution, researchers have developed a promising substitute using blood's oxygen-carrying component, hemoglobin.
St. Jude Medical, Inc., a global medical device company, today announced U.S. Food and Drug Administration (FDA) clearance, CE Mark approval and the launch of the EnSite Derexi™ module, which provides improved electrophysiology (EP) lab efficiency and workflow by enabling communication between the EnSite™ Velocity™ Cardiac Mapping System and the EP-Workmate™ Recording System.
› Verified 8 days ago
Rafid J Kakel, MD Preventive Medicine Medicare: Accepting Medicare Assignments Practice Location: 8726 Us Hwy 42, Florence, KY 41042 Phone: 859-647-2900 Fax: 859-647-0140 |